Here’s one FTSE 250 stock I’d buy in April

Our writer is itching to buy one FTSE 250 stock that ticks all of his boxes this month.

| More on:
Calendar showing the date of 5th April on desk in a house

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think 2024 could be the year of the mid-cap stock. As we close in on a new UK financial year, there’s one FTSE 250 stock in the healthcare sector that I am looking to buy this month.

This index represents companies ranked 101-350 by market capitalisation on the London Stock Exchange. It’s a diverse group, with a combined market value of over £320bn for savvy investors to go hunting in.

Where I’d spend my cash in April

My current favourite pick is in the biotechnology space. The company is PureTech Health (LSE: PRTC), a clinical-stage biotherapeutics group that develops medicines to fight serious diseases.

PureTech has developed 28 therapeutics and therapeutic candidates to date, focused on weight management, cognitive disorders, alopecia and more.

I first added PureTech to my watchlist back in October when it hit a 52-week low of 139p. Since then, the company’s share price has rebounded to 219p including a 6.0% gain in last Monday’s trade.

The biotechnology industry can be tricky to navigate for us stock pickers. While the potential rewards can be there for the right treatment, clinical trials incur steep, upfront research and development (R&D) costs, with uncertain success rates and significant regulatory risk.

That brings me to another reason why I’m looking to buy this FTSE 250 stock in April over other biotech names. Not only does PureTech continue to innovate with its R&D engine, but it has brought two candidates through both US FDA and European marketing approval.

The company is set for a busy couple of months with its anticipated results release this month, and a capital return project on the go.

PureTech plans to return $100m via a tender offer in the latest shareholder-friendly action from the company. That’s a fair chunk of change relative to the company’s £583m market capitalisation.

The recent $14bn sale of the PureTech-founded Karuna Therapeutics to Bristol Myers Squibb has been the catalyst for this latest payout to shareholders.

I see two positives from the Karuna transaction and subsequent payout. Firstly, this represents a successful ‘cradle to grave’ investment from PureTech as a “Founded Entity”. Secondly, I see the proposed capital return a sign that management are using excess cash to benefit shareholders.

Some investors may want to see more reinvestment from these biotech companies to fuel further growth. That is a valid point, but I think the staged nature of clinical trials make cash management an important part of being competitive in the marketplace.

Another thing that gives me peace of mind is a recent update . On 20 December 2023, the company said that it has £320m in cash and equivalents, giving it an “operational runway” until 2027.

Management noted PureTech’s “robust” balance sheet and I think it is comfortable with future liquidity needs. That means this is an opportunity to give shareholders some cash back in their pockets after the recent successful sale.

My time to buy

PureTech appears well capitalised, and has demonstrated clinical and commercial success. My current problem is having no spare cash available to pull the trigger and buy the stock. Hopefully that will change in the coming weeks!

If the company can beat guidance in its April full-year results, then I think it’s one FTSE 250 stock to seriously watch in 2024.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ken Hall has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10k in an ISA? Here’s how I’d target a regular £30k+ second income stream

Reliable dividends can help provide a lot more financial freedom. Here's how I'd aim for a substantial second income inside…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Lloyds share price hanging on to 50p ahead of Wednesday’s Q1 earnings report. Where to now?

Down in April and with low earnings expected this week, Mark David Hartley investigates where the Lloyds share price might…

Read more »

artificial intelligence investing algorithms
Investing Articles

Everyone’s talking about AI! Here’s 1 FTSE stock to consider buying for exposure

A hot topic right now is artificial intelligence (AI). This Fool explains how this FTSE stock could offer investors an…

Read more »

British Pennies on a Pound Note
Investing Articles

1 penny stock I’d buy today while it is 99p

Ben McPoland highlights Windward (AIM:WNWD), a fast-growing penny stock that could benefit from the artificial intelligence revolution.

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This forgotten FTSE 100 gem could be the best bargain on the stock market

The FTSE 100 is full to the brim of high-quality businesses. But this Fool has his eye on this 'forgotten'…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Here’s a FTSE 250 stock I’d put 100% of my money into

If this Fool could buy just one stock from the FTSE 250, Games Workshop would be his choice. Here, he…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

2 reasons Warren Buffett might love this stock, and 1 reason he might avoid it like the plague

Warren Buffett's one of the best stock pickers of all time. But would he approve of Barclays shares? This Fool…

Read more »

Union Jack flag triangular bunting hanging in a street
Investing Articles

Down 28% in a week! What’s going on with the share price of this FTSE 250 British icon?

There’s one stock in the FTSE 250 that took a bit of a battering last week. But I’m not surprised,…

Read more »